Table 1.

Baseline characteristics

N = 38	n (%), or median [range]
Age at diagnosis, y	40 [10‐66]
Male sex	16 (42)
Imatinib 1st line	29 (76)
Imatinib 2nd line	9 (24)
Imatinib dose, mg
100	1 (3)
200	2 (5)
300	4 (10)
400	25 (66)
600	5 (13)
800	1 (3)
Time on original imatinib, y	12 [1.5‐17]
Time to achieve CCyR, mo	6.2 [1.2‐29.2]
Time to achieve MMR, mo	11.7 [2.7‐67.7]
Time on generic imatinib, mon	19.4 [3.4‐46.3]